{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:06:16Z","timestamp":1792724776984,"version":"4.5.0"},"reference-count":93,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mature T- and natural killer (NK)\u2013cell neoplasms comprise a group of morphologically, immunophenotypically, molecularly, and clinically heterogeneous disorders with generally unfavorable outcome. Results of first-line chemotherapy are unsatisfactory for the most common T-cell lymphomas (peripheral T-cell lymphoma, not otherwise specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphomas; anaplastic lymphoma tyrosine kinase\u2013negative) as well as for many other entities. High-dose therapy followed by autologous hematopoietic stem cell transplantation (HSCT) is widely recommended for consolidation after a complete or partial remission is achieved. However, about one-third of patients never reach transplantation because of early relapse or refractoriness. Targeted therapies have recently been developed; combinations with chemotherapy may improve outcomes, but long-term results from prospective studies are largely missing. In this situation, allogeneic HSCT remains a valuable treatment option inducing long-lived remissions in about 30% to 50% of patients with relapsed and refractory T-cell lymphoma able to proceed to transplantation. Results of allogeneic transplantation for consolidation in first remission are less defined and its indications remain controversial. With growing evidence that haploidentical HSCT also works in lymphoma, more patients can be brought to transplantation. Decreasing the morbidity and mortality of allogeneic transplantation is a continuous challenge. Integrating new drugs into transplant concepts and setting up prospective studies involving allogeneic transplantation remain unmet needs that warrant urgent study in a group of disorders in which classical chemotherapy and new drugs have generated results, which are far from optimal until today.<\/jats:p>","DOI":"10.1182\/blood-2018-01-791335","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T14:40:35Z","timestamp":1524753635000},"page":"245-253","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":64,"title":["Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas"],"prefix":"10.1182","volume":"132","author":[{"given":"Norbert","family":"Schmitz","sequence":"first","affiliation":[{"name":"Department of Medicine A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111911090898000_B1","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017","edition":"Revised 4th ed"},{"issue":"25","key":"2019111911090898000_B2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111911090898000_B3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"2019111911090898000_B4","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1182\/blood-2013-01-453233","article-title":"How I treat NK\/T-cell lymphomas","volume":"121","author":"Tse","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111911090898000_B5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"118","author":"Bazarbachi","year":"2011","journal-title":"Blood"},{"issue":"20","key":"2019111911090898000_B6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111911090898000_B7","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"de Leval","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"2019111911090898000_B8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjh.13202","article-title":"Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era","volume":"168","author":"Petrich","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111911090898000_B9","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111911090898000_B10","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"16","key":"2019111911090898000_B11","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111911090898000_B12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111911090898000_B13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.14473","article-title":"How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future","volume":"176","author":"Schmitz","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111911090898000_B14","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","article-title":"Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma","volume":"38","author":"McKelvey","year":"1976","journal-title":"Cancer"},{"issue":"9","key":"2019111911090898000_B15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN Guidelines insights: non-Hodgkin\u2019s lymphomas, version 3.2016","volume":"14","author":"Horwitz","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 5","key":"2019111911090898000_B16","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d\u2019Amore","year":"2015","journal-title":"Ann Oncol"},{"issue":"18","key":"2019111911090898000_B17","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111911090898000_B18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111911090898000_B19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"2019111911090898000_B20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"15","key":"2019111911090898000_B21","doi-asserted-by":"crossref","first-page":"S7500","DOI":"10.1200\/JCO.2016.34.15_suppl.7500","article-title":"Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: final results of 116 patients treated in the international ACT-2 phase III trial","volume":"34","author":"Trumper","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111911090898000_B22","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"23","key":"2019111911090898000_B23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.V126.23.253.253","article-title":"Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: results of the Bel-CHOP Phase 1 Trial [abstract]","volume":"126","author":"Johnston","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111911090898000_B24","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111911090898000_B25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"issue":"11","key":"2019111911090898000_B26","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111911090898000_B27","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111911090898000_B28","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111911090898000_B29","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3324\/haematol.2015.135400","article-title":"Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients","volume":"101","author":"Lamarque","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"2019111911090898000_B30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2019111911090898000_B31","first-page":"2790","article-title":"Five-year survival results: frontline brentuximab vedotin in combination with CHP in patients with CD30-expressing peripheral T-cell lymphomas [abstract]","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2019111911090898000_B32","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V118.21.3091.3091","article-title":"Allogeneic transplant following brentuximab vedotin treatment in patients with relapsed or refractory CD30+ lymphomas","volume":"118","author":"Illidge","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2019111911090898000_B33","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111911090898000_B34","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111911090898000_B35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111911090898000_B36","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2019111911090898000_B37","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2019111911090898000_B38","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","article-title":"Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells","volume":"129","author":"Watanabe","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2019111911090898000_B39","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111911090898000_B40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111911090898000_B41","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111911090898000_B42","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111911090898000_B43","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"},{"issue":"15 suppl","key":"2019111911090898000_B44","first-page":"8507","article-title":"Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: results of the interim analysis of the AATT trial","volume":"33","author":"Schmitz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111911090898000_B45","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","article-title":"High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"20","author":"Nickelsen","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111911090898000_B46","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.bbmt.2015.12.004","article-title":"Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphomas as front-line consolidation or in the relapsed\/refractory setting: a systematic review\/meta-analysis","volume":"22","author":"El-Asmar","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"2019111911090898000_B47","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111911090898000_B48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"2019111911090898000_B49","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"26","key":"2019111911090898000_B50","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111911090898000_B51","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111911090898000_B52","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111911090898000_B53","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"2019111911090898000_B54","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann Oncol"},{"issue":"24","key":"2019111911090898000_B55","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111911090898000_B56","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2011.574754","article-title":"Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control","volume":"52","author":"Zain","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111911090898000_B57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bmt.2011.16","article-title":"Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas","volume":"47","author":"Delioukina","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2019111911090898000_B58","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.bbmt.2013.07.003","article-title":"Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin\u2019s lymphoma","volume":"19","author":"Czajczynska","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2019111911090898000_B59","first-page":"4597","article-title":"Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis [abstract]","volume":"130","author":"Mehta-Shah","year":"2017","journal-title":"Blood"},{"key":"2019111911090898000_B60","article-title":"Allogeneic stem cell transplantation for peripheral T-cell lymphomas: a study of 284 patients from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire","author":"Mamez"},{"issue":"15","key":"2019111911090898000_B61","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111911090898000_B62","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","article-title":"Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms","volume":"130","author":"Murashige","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111911090898000_B63","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/bmt.2014.65","article-title":"Allogeneic haematopoietic SCT for natural killer\/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group","volume":"49","author":"Tse","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111911090898000_B64","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/bmt.2010.284","article-title":"Donor lymphocyte infusion for extranodal NK\/T cell lymphoma, nasal type, relapsed after allogeneic hematopoietic SCT","volume":"46","author":"Ito","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111911090898000_B65","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/sj.bmt.1704897","article-title":"Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma","volume":"35","author":"Mansour","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111911090898000_B66","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2014.280","article-title":"Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party","volume":"29","author":"Tanase","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"2019111911090898000_B67","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","article-title":"Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK\/T Cell Lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111911090898000_B68","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111911090898000_B69","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2004-11-4193","article-title":"Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia\/lymphoma","volume":"105","author":"Okamura","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111911090898000_B70","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"issue":"10","key":"2019111911090898000_B71","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/bmt.2014.143","article-title":"Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP","volume":"49","author":"Bazarbachi","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111911090898000_B72","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/bmt.2016.313","article-title":"Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia\/lymphoma, a Japanese nation-wide study","volume":"52","author":"Fujiwara","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2019111911090898000_B73","article-title":"Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis [published online ahead of print 25 January 2018]","author":"Fuji","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111911090898000_B74","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3324\/haematol.2017.164996","article-title":"Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation","volume":"102","author":"Fuji","year":"2017","journal-title":"Haematologica"},{"issue":"25","key":"2019111911090898000_B75","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides","volume":"23","author":"Molina","year":"2005","journal-title":"J Clin Oncol"},{"issue":"29","key":"2019111911090898000_B76","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111911090898000_B77","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood.V122.21.2094.2094","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: the experience of the EBMT Lymphoma Working Party with an extended five-year follow up [abstract]","volume":"122","author":"Duarte","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111911090898000_B78","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"2019111911090898000_B79","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111911090898000_B80","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"issue":"18","key":"2019111911090898000_B81","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111911090898000_B82","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT","volume":"121","author":"Jantunen","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111911090898000_B83","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23992","article-title":"Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort","volume":"90","author":"Nijeboer","year":"2015","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111911090898000_B84","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group","volume":"27","author":"Brugi\u00e8res","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111911090898000_B85","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2006.06004.x","article-title":"Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-M\u00fcnster group report","volume":"133","author":"Woessmann","year":"2006","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111911090898000_B86","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2141.2005.05910.x","article-title":"Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan","volume":"132","author":"Mori","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111911090898000_B87","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"2019111911090898000_B88","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111911090898000_B89","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2019111911090898000_B90","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111911090898000_B91","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111911090898000_B92","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"4 suppl","key":"2019111911090898000_B93","first-page":"95","article-title":"Allogeneic stem cell transplantation for patients with relapsed or chemorefractory T-cell lymphoma: role of high intensity conditioning","volume":"22","author":"Glass","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/3\/245\/1372137\/blood791335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/3\/245\/1372137\/blood791335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T04:19:56Z","timestamp":1604204396000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/3\/245\/39241\/Allogeneic-hematopoietic-stem-cell-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-01-791335","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733117869.793577567","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]}}}